ORIGINAL ARTICLE   Free access

Esperienze Dermatologiche 2019 March;21(1):1-5

DOI: 10.23736/S1128-9155.19.00478-3

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Leniqol cream in radio-dermatitis

Giada MARAMALDI ¹ ✉, Antonella RIVA ¹, Stefano TOGNI ¹, Maria R. CESARONE ², Ambra CORTI ³, Gianni BELCARO ²

¹ Indena S.p.A, Milan, Italy; ² Department of Medical Science, IRVINE3 Vascular Lab, Chieti-Pescara University, Chieti, Italy; ³ Polistudium SRL, Milan, Italy

BACKGROUND: Leniqol is a smooth and extremely fluid emulsion containing a blend of natural active ingredients specifically combined to counteract skin discomfort. In this pilot study we evaluated the efficacy and safety of Leniqol topical formulation as soothing and lenitive agent in oncological patients undergoing radiotherapy.
METHODS: We enrolled patients receiving radiation therapy for different types of cancer. All study participants freely decided to follow either a standard management (SM) protocol, consisting in the application of dexpanthenol (N=19), or SM associated with Leniqol (N=22).
RESULTS: Patients treated with Leniqol showed a beneficial effect, and after 4 weeks of treatment they reported a more evident and consistent reduction in radiodermatitis symptoms, namely skin redness (82% vs. 37%), skin peeling (77% vs. 48%), skin edema (91% vs. 68%) and local pain (86% vs. 58%), compared to patients in the control group.
CONCLUSIONS: This pilot investigation suggests that Leniqol may help reduce radiation-induced skin damage, and might therefore be considered as a coadjuvant treatment in association with SM to help reduce skin discomfort and support quality of life in cancer patients undergoing radiation therapy.

KEY WORDS: Radiodermatitis; Erythema; Therapeutics